Clinical Trial Update: Antiangiogenic Peptide Vaccine Therapy With Gemcitabine in Treating Patient With Pancreatic Cancer (Phase1/2) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating an antiangiogenic peptide vaccine therapy in combination with gemcitabine for pancreatic cancer; the study status is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• antiangiogenic peptide vaccine therapy

Snippet

Sponsor: Fukushima Medical University | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED